Financial Performance - Total product revenue for the year ended December 31, 2025, was $37.1 million, an increase of 4.1% compared to $35.6 million in 2024[250]. - Gross profit for 2025 was approximately $26.5 million, representing a gross margin of 71.5%, up from 69.9% in 2024[256]. - Loss from operations improved by 10.4% to approximately $14.7 million in 2025, compared to $16.5 million in 2024, driven by revenue growth and gross margin improvement[260]. - Research and development expenses decreased by 33.2% to approximately $5.1 million in 2025, down from $7.6 million in 2024, due to the completion of the STAR-T clinical trial[257]. - Selling, general and administrative expenses increased by 5% to approximately $35.6 million in 2025, primarily due to higher legal and regulatory costs[258]. - Net interest expense for 2025 was approximately $2.6 million, an increase from $1.4 million in 2024, due to interest incurred on the credit facility[261]. - Benefit from income taxes was approximately $0.4 million for 2025, down from $1.7 million in 2024, due to the utilization of the New Jersey Technology Business Tax Certificate Transfer Program[265]. Strategic Initiatives - The company initiated a strategic workforce and cost reduction plan, resulting in a restructuring charge of approximately $0.5 million in 2025[259]. - The company expects to reach operating cash flow break-even in the second half of 2026 following the strategic workforce and cost reduction plan[252]. - The company plans to file a new De Novo application for DrugSorb-ATR with the FDA, following an appeal meeting that affirmed no safety-related issues with the device[250]. - The company initiated a Strategic Workforce and Cost Reduction Plan, reducing its workforce by approximately 10% and expects to reach operating cash flow break-even in the second half of 2026[275]. Financial Position - As of December 31, 2025, current assets were approximately $20.6 million and current liabilities were approximately $9.7 million[266]. - As of December 31, 2025, the company had approximately $7.8 million in cash, which may not be sufficient to fund operations beyond the next twelve months[276]. - An effective shelf registration statement allows the company to raise up to $150 million, with approximately $149.7 million available as of December 31, 2025[267]. - The company entered into a Loan and Security Agreement with Avenue Capital Group for up to $20 million, with the first tranche of $15 million disbursed under specific conditions[268]. - The Amended Loan and Security Agreement provides access to an additional $2.5 million, with an extension of the interest-only period to December 31, 2026, subject to FDA approval[281]. Capital Raising Activities - The company raised $6.25 million from a rights offering, with proceeds used to satisfy a debt covenant and release $5 million of restricted cash[273]. - The Company raised aggregate gross proceeds of $6.25 million from the Rights Offering, with $5.4 million net of fees[287]. - Participants received Units comprising one share of common stock and two Right Warrants, with the potential to issue an additional 6.25 million shares upon exercise[287]. - Approximately 1.4 million Series A Right Warrants were exercised at an exercise price of $1.13 per warrant, generating an additional $1.6 million in gross proceeds[287]. - The expiration date of the Series B Right Warrants was extended from April 10, 2025, to June 10, 2025[287]. - The Series B Right Warrants expired worthless due to the 5-day volume weighted average price of Common Stock being below the minimum required price of $2.00[287]. Tax and Valuation Considerations - The Company evaluates uncertain tax positions based on estimates and assumptions, which may differ from actual results[289]. - The fair value of warrants is estimated using the Black-Scholes or Monte Carlo pricing models, requiring significant estimates regarding inputs[295]. - Changes in assumptions used for estimating the fair value of warrants could materially affect the financial statements[298]. - The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense[291]. - Deferred tax assets are evaluated for valuation allowances based on expectations of future taxable income, which could impact financial statements[292]. Other Financial Metrics - The company reported a gain on foreign currency transactions of approximately $9.3 million in 2025, compared to a loss of $4.2 million in 2024, attributed to the increase in the Euro to U.S. dollar exchange rate[262]. - Loss on abandoned patents increased by approximately $0.2 million or 67.4%, totaling $0.6 million for the year ended December 31, 2025, compared to $0.3 million for 2024[264].

Biotechnology and Drug Development - As of December 31, 2025, the company manages a diverse portfolio of four wholly owned subsidiaries in the medical aesthetics and biopharmaceutical sectors[29]. - The divestiture of Elevai Skincare Inc. on January 16, 2025, allows the company to focus resources on biotechnology assets, enhancing growth opportunities[30]. - Northstrive Biosciences Inc. targets the obesity market, with over 40% of U.S. adults affected, projected to rise to 50% by 2030, creating a $100 billion market opportunity[32]. - The lead asset, EL-22, has completed a Phase 1 clinical trial in South Korea, showing safety and tolerability, with no dropouts due to adverse events[34]. - The company aims to submit an Investigational New Drug application for EL-22 in 2025, contingent on sufficient working capital[36]. - The second asset, EL-32, is in preclinical development, targeting muscle preservation in weight loss treatments, with promising results in mouse models[37]. - Northstrive Biosciences is developing EL-22, an engineered probiotic, with the potential to treat obesity while preserving muscle mass, targeting a market projected to reach $100 billion by 2030[62][78]. - EL-22 has shown a statistically significant increase in anti-myostatin IgG antibody concentration and a decrease in creatine kinase levels, indicating reduced muscle destruction[87]. - Northstrive Biosciences plans to complete an IND submission for EL-22 in 2025 and initiate clinical trials in the U.S. contingent upon FDA approval[86]. - Northstrive's EL-32 is positioned for muscle preservation in weight loss treatments, addressing an unmet need in the obesity treatment landscape[66]. - The weight-loss drug market, driven by GLP-1 receptor agonists, is experiencing significant growth, with existing drugs showing that up to 40% of weight loss may come from lean muscle mass loss[79]. - The biotechnology market is projected to grow significantly, with the anti-obesity drug market potentially reaching $100 billion by 2030[98]. - The product candidates EL-22 and EL-32 are believed to represent the only oral myostatin formulations currently in development, providing a potential competitive advantage over existing injectable approaches[98]. - The success of the Licensed Products depends on successful completion of preclinical studies and clinical trials, as well as obtaining regulatory approvals[200]. - The commercial success of the Licensed Products will be contingent upon establishing manufacturing relationships and maintaining patent protection[200]. - The biotechnology subsidiary, Northstrive Biosciences, has not yet commercialized any therapeutic products, with lead asset EL-22 having completed a Phase 1 clinical trial in South Korea but not yet tested in the U.S.[192]. Financial Performance and Capital Requirements - As of December 31, 2025, the company had net working capital of $2,928,959, down from $4,251,867 in 2024, and an accumulated deficit of $21,017,440, increasing from $13,269,627 in 2024[159]. - The company incurred net losses of $7,747,813 for the year ended December 31, 2025, compared to $6,245,737 for the year ended December 31, 2024[161]. - Operating cash consumption significantly exceeds revenue, indicating unsustainable operations without continued access to capital markets[162]. - The company requires significant additional capital to develop its products and businesses, with uncertain funding availability[163]. - The existing equity purchase facility may lead to substantial dilution for stockholders and downward pressure on the stock price[165]. - Future financing may not be available on acceptable terms, potentially leading to operational limitations and adverse effects on financial condition[173]. - The divestiture of the Elevai Skincare business includes potential earn-out payments contingent on revenue milestones, with no assurance of achievement[174]. - The company operates as a diversified holding company, increasing complexity in management and financial reporting across multiple industries[178]. - Acquisitions are a core growth strategy, but they involve significant risks, including integration challenges and potential underperformance of acquired businesses[184]. - Goodwill recorded on the consolidated balance sheet may be subject to impairment, which could adversely affect financial results[189]. Market and Competitive Landscape - The global biotechnology market was valued at approximately $1.37 trillion in 2022, with a projected CAGR of 12.8% from 2023 to 2030, driven by advancements in gene therapies and biologics[77]. - The precision machining market is expected to grow at a CAGR of approximately 8.1% from 2026 to 2033, with a valuation of approximately $123 billion in 2025[80]. - The global aerospace parts manufacturing market was valued at approximately $913 billion in 2023, with a projected CAGR of 4.2% from 2024 to 2030[80]. - The obesity and muscle preservation therapeutic market is highly competitive, with key players including Novo Nordisk, Eli Lilly, Pfizer, and Biohaven, all of which have greater financial and technical resources[93][94]. - Pacific Sun Packaging operates in a highly competitive industry, facing pricing pressure from larger competitors, which could adversely affect revenue and margins[210]. - The precision machining and specialty metals CNC market is competitive, with AGA Precision Systems differentiating itself through specialized machining capabilities and established customer relationships[96]. Regulatory and Compliance Issues - The company is subject to extensive government regulations regarding the research, development, and approval of its biologic drug candidates, which may change over time[125]. - The FDA has a goal date of ten months from the date of filing to review and act on a Biologics License Application (BLA) submission[135]. - A Complete Response Letter (CRL) indicates that the BLA cannot be approved in its present form, detailing specific deficiencies identified by the FDA[137]. - Post-marketing requirements (PMRs) may include Phase 4 studies to gain additional experience from the treatment of patients after initial marketing approval[138]. - Compliance with the International Traffic in Arms Regulations (ITAR) is mandatory for precision manufacturing operations, with annual registration renewal required[142]. - The company’s precision manufacturing operations are subject to federal and state occupational safety and health laws, with potential fines and citations for non-compliance[145]. - The company must comply with environmental regulations, including the Clean Air Act and Clean Water Act, to avoid fines and operational restrictions[146]. - The company’s specialty packaging operations must adhere to electrostatic discharge protection standards, which are often required by customers in the semiconductor industry[150]. - The company may face significant regulatory burdens if deemed an "investment company" under the Investment Company Act of 1940[224]. Operational Risks and Challenges - The company relies on a limited number of suppliers for raw materials, and disruptions could adversely affect the ability to fulfill customer orders[212]. - Disruptions in supply chains could increase costs and impair the ability to fulfill customer orders, adversely affecting revenue and margins[221]. - The company may face disputes or financial obligations related to earn-out and contingent consideration arrangements from acquisitions, impacting overall costs[190]. - The development of therapeutic product candidates could expose the company to significant legal and regulatory risks, affecting timelines and costs[197]. - AGA Precision Systems incurred significant repair and maintenance costs following acquisitions, which may require ongoing capital investment[215]. - The company has historically operated without a formal sales and marketing function, potentially limiting growth opportunities[216]. - Operations across multiple industries expose the company to diverse market risks, which may not mitigate overall risk as expected[217]. - A portion of revenue may depend on a limited number of key customers, risking significant adverse effects on revenue if relationships are not maintained[220]. - Non-compliance with anti-corruption and anti-bribery laws could expose the company to significant penalties and reputational harm[227]. Employee and Management Structure - The company has 32 full-time and 2 part-time employees, focusing on competitive compensation and a positive work environment to attract and retain talent[123]. - The principal executive office is located in Newport Beach, CA, with a monthly rent of $9,273.50 for a 1,650 square feet space[121]. - The company engages with institutional investors and industry participants to enhance awareness of its diversified business model and growth strategy[116]. - The company emphasizes flexible M&A and licensing models to create value for shareholders, allowing for strategic acquisitions and potential spin-offs[115].

Financial Performance - The company's revenue for 2025 decreased by 21.8% year-over-year to $29.7 million, primarily due to a 30.8% decline in hashprice from $54.45 to $37.68[16] - Gross profit for 2025 was $6.5 million, with a gross margin decline from 25% in 2024 to 22% in 2025, attributed to weaker hashprice[16] - The net loss for 2025 was $57.0 million, slightly improved from a net loss of $58.3 million in 2024[21] - Adjusted EBITDA for 2025 decreased to -$13.2 million, down from a positive $942k in 2024, due to revenue declines and increased expenses[21] - Total revenue for Soluna Holdings in 2025 was $29.717 million, a decrease of 21.8% from $38.021 million in 2024[29] - Cryptocurrency mining revenue decreased to $11.406 million in 2025, down 32.9% from $17.027 million in 2024[29] - Data hosting revenue also declined to $16.998 million, a decrease of 10.0% from $18.838 million in 2024[29] - The operating loss for 2025 was $33.681 million, an improvement from a loss of $47.523 million in 2024[29] - Net loss attributable to Soluna Holdings was $53.411 million in 2025, compared to a net loss of $63.334 million in 2024[29] - Basic and diluted loss per share improved to $2.38 in 2025 from $14.94 in 2024[29] - For the year ended December 31, 2025, the net loss before taxes was $(59,307) million, slightly improved from $(60,787) million in 2024[36] - Adjusted EBITDA for the year ended December 31, 2025, was $(13,229) million, compared to $942 million in 2024, indicating a significant decline in operational performance[39] Cash and Liquidity - Soluna's total cash position increased by 750% to $88.8 million, with approximately $142 million raised in capital during 2025[5] - The company entered 2026 with a current ratio of 1.9x, indicating a strong liquidity position to support future growth initiatives[8] - Cash and cash equivalents rose significantly to $76.423 million in 2025 from $7.843 million in 2024[26] - The company ended the period with cash and restricted cash totaling $88,843 thousand, a significant increase from $10,453 thousand at the beginning of the period[31] - Net cash used in operating activities was $9,149 thousand for 2025, an increase from $5,069 thousand in 2024, reflecting higher operational expenditures[31] - Net cash provided by financing activities reached $119,392 thousand in 2025, a substantial increase from $18,318 thousand in 2024, driven by various stock issuances[31] Operational Capacity and Projects - The operational capacity doubled in 2025, with the power pipeline expanding to over 4.3 GW, driven by new project developments[2] - Project Dorothy 2, with a capacity of 48 MW, was completed and fully operational in November 2025, enhancing profitability and customer satisfaction[6] - The construction of Project Kati 1 (83 MW) commenced in Q3 2025, with revenue generation expected in the first half of 2026[6] Expenses and Costs - SG&A expenses increased by $11.9 million year-over-year, driven by strategic investments in growth initiatives[16] - The company incurred total segment costs of revenue amounting to $24,255 thousand, with utility costs contributing $8,910 thousand and wages, benefits, and employee-related costs at $3,733 thousand[33] - The total segment cost of revenue for the year ended December 31, 2025, was $23,259 million, reflecting increased operational costs[37] - The company recognized stock-based compensation expenses of $10,566 thousand in 2025, up from $5,311 thousand in 2024, indicating increased employee incentives[31] Assets and Liabilities - Total assets increased to $187.944 million as of December 31, 2025, compared to $88.040 million in 2024[26] - Total liabilities increased to $75.698 million in 2025, up from $60.678 million in 2024[26] Fair Value Adjustments - The company reported a fair value adjustment of $23,680 thousand, which contributed positively to the cash flow from operating activities[31] - The company experienced a fair value adjustment loss of $23,681 million in 2025, significantly impacting the financial results[39] - The company reported a fair value adjustment loss of $118,000 in Q3 2025, compared to a significant loss of $22,047,000 in Q2 2025, suggesting improved asset valuation management[41]

Financial Performance - Revenue for 2025 decreased by 21.8% year-over-year to $29.7 million, primarily due to a 30.8% decline in hashprice[16][21] - Gross profit for 2025 was $6.5 million, with a gross margin drop from 25% in 2024 to 22% in 2025[16][21] - Adjusted EBITDA for 2025 declined to -$13.2 million, a decrease of $14.2 million from the previous year[21] - Total revenue for Soluna Holdings in 2025 was $29.717 million, a decrease of 21.8% from $38.021 million in 2024[29] - Cryptocurrency mining revenue decreased to $11.406 million in 2025, down 32.9% from $17.027 million in 2024[29] - Data hosting revenue also declined to $16.998 million, a decrease of 10.0% from $18.838 million in 2024[29] - Operating loss for 2025 was $33.681 million, an improvement from a loss of $47.523 million in 2024[29] - Net loss attributable to Soluna Holdings in 2025 was $53.411 million, compared to a net loss of $63.334 million in 2024[29] - Basic and diluted loss per share improved to $2.38 in 2025 from $14.94 in 2024[29] - Net loss for the year ended December 31, 2025, was $56,991, compared to a loss of $58,300 in 2024, representing a decrease of 2.2%[31] Cash and Liquidity - Soluna's total cash position increased by 750% to $88.8 million, with approximately $142 million raised in capital during 2025[5][16] - The current ratio improved to 1.9x, indicating a stronger liquidity position heading into 2026[8] - Cash and cash equivalents rose significantly to $76.423 million in 2025, compared to $7.843 million in 2024[26] - Cash and restricted cash at the end of the period rose to $88,843 from $10,453 at the beginning of the period, reflecting a significant increase[31] - Net cash used in operating activities increased to $9,149 in 2025 from $5,069 in 2024, indicating a higher cash outflow[31] Assets and Liabilities - Total assets increased to $187.944 million as of December 31, 2025, up from $88.040 million in 2024[26] - Total liabilities increased to $75.698 million in 2025, compared to $60.678 million in 2024[26] Project Developments - The power pipeline expanded to over 4.3 GW, driven by new project developments and partnerships[2][6] - The completion of Project Dorothy 2 (48 MW) in November 2025 enhanced operational efficiency and customer satisfaction[6][21] - Construction of Project Kati 1 (83 MW) commenced in Q3 2025, with revenue generation expected in the first half of 2026[6][21] - Soluna signed an MOU with Metrobloks for Project Kati 2, planning to develop over 300 MW of AI and HPC data center capacity[6] Operating Expenses - SG&A expenses increased by $11.9 million year-over-year, reflecting strategic investments in growth initiatives[16] - The company incurred depreciation expenses of $6,852, up from $6,152 in 2024, indicating increased asset utilization[31] - The company made significant investments in property, plant, and equipment totaling $28,065, compared to $8,853 in 2024, reflecting a focus on expansion[31] Segment Performance - Total segment cost of revenue was $24,255, with the highest costs attributed to utility expenses at $8,910 and wages at $3,733[33] - The company reported a segment operating income of $1,798, with a loss in Cryptocurrency Mining of $630 and a profit in Data Center Hosting Services of $2,677[33] - For the year ended December 31, 2025, the projected segment operating income is $1,798 million, indicating a potential recovery from the previous year's losses[36] Interest and Fair Value Adjustments - Interest expense, net for Q3 2025 was $838,000, compared to $1,196,000 in Q2 2025, with a total of $4,835,000 for the year ended December 31, 2025[41] - Fair value adjustment loss for Q3 2025 was $118,000, while the total for the year ended December 31, 2025 was $23,681,000[41] Non-controlling Interests - Contributions from non-controlling interest increased to $29,559 from $14,735, indicating stronger financial backing from minority stakeholders[31]

Financial Position - Neumora reported a cash position of $182.5 million as of December 31, 2025, expected to support operations into Q3 2027[15]. - Neumora's total assets decreased to $191.0 million as of December 31, 2025, down from $317.0 million in 2024[20]. Research and Development - Research and development expenses for Q4 2025 were $44.7 million, a decrease from $45.9 million in Q4 2024; full-year R&D expenses were $176.1 million, down from $200.9 million in 2024[15]. - NMRA-511 demonstrated a Cohen's d effect size of 0.34 on the CMAI total score and 0.51 on the CMAI aggression sub-factor score at Week 8 in a pre-specified analysis of 53 patients[6]. - NMRA-898 has shown an approximately 80-100-hour half-life in humans, supporting potential once-daily dosing[13]. - Neumora plans to initiate a Phase 2 study with NMRA-511 in Alzheimer's disease agitation in Q1 2027[5]. - NMRA-215's 12-week diet-induced obesity study supports its potential use in switch and maintenance settings, with clinical studies expected to start in Q1 2027[9]. Expenses - General and administrative expenses for Q4 2025 were $13.8 million, compared to $17.0 million in Q4 2024; full-year G&A expenses were $60.1 million, down from $62.5 million in 2024[15]. - The net loss for Q4 2025 was $59.4 million, slightly higher than the $58.8 million loss in Q4 2024; the full-year net loss was $236.9 million, compared to $243.8 million in 2024[15]. Clinical Trials - The KOASTAL-2 and -3 studies were fully enrolled in Q1 2026, with over 400 patients in each study, and a joint topline data readout is expected in Q2 2026[7].

Financial Performance - Sales for the second quarter increased 3.0% to $20.8 billion compared to the same period in fiscal year 2025[5] - Gross profit increased 3.9% to $3.8 billion, with a gross margin of 18.3%, reflecting a 15 basis point increase[6] - Operating income decreased 2.8% to $692 million, while adjusted operating income increased 3.1% to $807 million[3] - Net earnings decreased 4.2% to $389 million, but adjusted net earnings increased 3.9% to $476 million[3] - Sales for the 13-week period ended December 27, 2025, were $20,762 million, an increase of 3.0% compared to $20,151 million for the same period in 2024[24] - Gross profit for the 26-week period ended December 27, 2025, was $7,693 million, up from $7,403 million in 2024, reflecting a growth of 3.9%[24] - Net earnings for the 26-week period ended December 27, 2025, were $866 million, a decrease of 3.3% from $896 million in the prior year[26] - Basic earnings per share for the 13-week period ended December 27, 2025, were $0.81, compared to $0.83 for the same period in 2024[24] - For the 26-week period, Sysco reported GAAP sales of $41,910 million, a 3.1% increase from $40,634 million in the prior year[36] - Diluted earnings per share (GAAP) decreased to $1.80, down 1.1% from $1.82[37] Cash Flow and Shareholder Returns - Cash flow from operations was $611 million, and free cash flow was $413 million for the first 26 weeks of fiscal year 2026[13] - The company returned $518 million to shareholders via dividends during the first 26 weeks of fiscal year 2026[13] - Free cash flow for the 26-week period ended December 27, 2025, was $413 million, up from $331 million in the prior year, reflecting an increase of $82 million[43] Sales Growth - U.S. Foodservice local case volume grew by 1.2%, contributing to overall positive case growth[1] - International Foodservice Operations sales increased 7.3% to $4.0 billion, with a gross profit increase of 9.5% to $832 million[11] - U.S. foodservice operations sales increased by $339 million, or 2.4%, reaching $14,383 million[38] - International foodservice operations sales grew by $271 million, or 7.3%, totaling $3,999 million[38] - Total Sysco sales rose by $611 million, or 3.0%, to $20,762 million[39] Operating Expenses - Operating expenses increased by 5.5% to $3,100 million, with adjusted operating expenses (Non-GAAP) at $2,985 million, reflecting a 4.1% increase[33] - Operating expenses for Total Sysco increased by 5.4% to $6,200 million, with adjusted operating expenses rising by 4.2% to $5,987 million[41] Debt and Leverage - Long-term debt stood at $12,440 million as of December 27, 2025, slightly up from $12,360 million as of June 28, 2025[25] - Total Debt (GAAP) stands at $13,590 million, with Net Debt (Non-GAAP) at $12,368 million[48] - The Net Debt to Adjusted EBITDA ratio (Non-GAAP) is 2.86, indicating the company's leverage relative to its earnings[48] Adjusted Metrics - Adjusted net earnings for fiscal 2026 were $1,028 million, a 3.1% increase from $997 million in fiscal 2025[37] - Adjusted EBITDA growth is considered a key measure of financial performance, with management emphasizing its importance for consistent period comparisons[44] - Adjusted EBITDA for the 13-week period, after certain item adjustments, increased to $1,001 million, reflecting a 3.3% rise from $969 million in the previous year[45] - Adjusted EBITDA for the 26-week period was $2,071 million, an increase of 1.7% compared to $2,037 million in the prior year[46] Strategic Focus - Sysco continues to focus on growth through acquisitions, excluding acquisition-related costs from its non-GAAP financial measures to enhance comparability[31] - The company reported a significant increase in acquisition-related costs, rising to $23 million from $8 million year-over-year, indicating ongoing strategic investments[45] - The impact of restructuring and transformational project costs was significant, with a total impact of $114 million on operating expenses for Total Sysco[41] - The impact of restructuring and transformational project costs in fiscal 2026 included $21 million in severance charges and $93 million in transformation initiative costs[37]

Revenue Performance - Total revenues decreased to $2,073,557 in 2025 from $3,496,405 in 2024, a decline of approximately 40.7%[435] - Service business revenue fell to $1,843,968 in 2025 from $3,091,903 in 2024, a decrease of about 40.3%[436] - Digital revenue decreased to $168,240 in 2025 from $327,802 in 2024, representing a decline of approximately 48.7%[437] - Rental revenue was $61,349 in 2025, down from $76,700 in 2024, a decrease of about 20.0%[438] - Related party service revenue for 2025 totaled $58,861, a decrease of 83.9% from $364,336 in 2024, representing 2% of total service revenue[461] Expenses and Losses - General and administrative expenses reduced to $3,818,580 in 2025 from $4,039,243 in 2024, a decrease of approximately 5.5%[448] - Loss from operations increased to $2,152,416 in 2025 compared to $969,278 in 2024, reflecting a rise of approximately 121.5%[441] - Net loss for 2025 was $2,982,333, significantly higher than the net loss of $725,827 in 2024, an increase of approximately 310.5%[454] - The company recorded net other expenses of $817,676 in 2025, compared to net other income of $247,890 in 2024[449] Related Party Transactions - Digital revenue from related parties in 2024 was $21,000, with 95% generated from the CEO, Mr. Lee[463] - Cost of service revenue to related parties increased to $14,642 in 2025 from $10,934 in 2024[464] - Related party G&A expenses decreased to $145,505 in 2025 from $149,817 in 2024[467] - Other income from related parties was $38,729 in 2025, down from $47,635 in 2024[471] - Interest income from related parties increased to $6,103 in 2025 from $5,073 in 2024[472] - Gain on disposal of related party investments was $39,800 in 2025, a significant decrease from $324,917 in 2024[474] Cash Flow and Financing - Cash balance decreased to $636,659 as of December 31, 2025, from $1,124,818 in 2024, a decline of 43.4%[499] - Net cash used in operating activities increased to $1,790,250 in 2025 from $1,360,454 in 2024[503] - Net cash provided by investing activities was $37,162 in 2025, a decrease from $601,277 in 2024, primarily due to lower proceeds from investment disposals[508][509] - Financing activities generated net cash of $1,234,025 in 2025, primarily from the sale of Common Stock in private placements totaling $1,235,000[510] - The company issued 1,050,000 shares of Common Stock in private placements in 2025, increasing total shares outstanding to 8,625,813[511] - In 2024, the company did not issue any shares, maintaining 7,575,813 shares outstanding as of December 31[512] Future Outlook - The company expects slight recovery in service business revenue as it explores new markets[435] - The company reported net cash used in operating activities over the past two years, indicating ongoing operational challenges[507] - The company is classified as a smaller reporting company and is not required to provide detailed market risk disclosures[513] Acquisitions - The acquisition of the remaining 40% shares of Forward Win International Limited was completed in April 2024, making it a wholly owned subsidiary[451] Non-Cash Expenses - Non-cash expenses for 2025 included depreciation and amortization of $240,147, impairment of property and equipment of $813,552, and impairment of goodwill of $6,035, totaling significant non-cash charges[505] - In 2024, non-cash expenses included depreciation and amortization of $245,921 and impairment of goodwill of $82,561, with total non-cash income from gains on disposal of investments amounting to $346,551[506]

Financial Performance - The company reported a net loss of $36.7 million for the year ended December 31, 2024, which decreased to $26.6 million for the year ended December 31, 2025, representing a reduction of 28%[402] - For the year ended December 31, 2025, the company reported a net loss of $26.6 million, with an accumulated deficit of $127.8 million as of the same date[411] - The company has an accumulated deficit of $127.8 million as of December 31, 2025[391] Expenses - Research and development expenses decreased by approximately $10.9 million, or 54%, from $20.0 million in 2024 to $9.1 million in 2025, primarily due to reduced drug development costs[403] - General and administrative expenses increased by $8.3 million, or 69%, from $12.1 million in 2024 to $20.4 million in 2025, driven by higher marketing and consulting costs[404] - Net cash used in operating activities was $31.3 million for the year ended December 31, 2025, primarily due to development costs and corporate expenditures[418] - The company incurred net cash used in investing activities of $12.1 million for the year ended December 31, 2025, mainly due to the purchase of marketable securities[421] Financing Activities - The company sold 3,123,537 shares of common stock at an average price of $6.51 per share, resulting in net proceeds of approximately $19.6 million[395] - The company entered into a sales agreement to offer and sell shares of common stock with an aggregate offering price of up to $100 million, resulting in net proceeds of approximately $45.2 million for the year ended December 31, 2025[410] - Net cash provided by financing activities was $46.5 million during the year ended December 31, 2025, primarily from sales under the sales agreement with Guggenheim Securities LLC[422] Future Plans and Expectations - The company plans to resubmit its New Drug Application (NDA) for oxylanthanum carbonate (OLC) to the FDA, with a target action date set for June 29, 2026[395] - The company expects significant increases in operating expenses as it advances product candidates through clinical development and seeks regulatory approval[391] - The company anticipates future revenue streams from collaboration or licensing agreements, as well as product sales[408] - The company plans to continue its drug discovery efforts and clinical trials, which will significantly influence future capital requirements[414] - The company expects to continue incurring losses and will need to raise additional capital for clinical trials and product development initiatives[413] - The company anticipates that its current cash will be sufficient to fund operations for more than 12 months from the date of the report[412] Market Context - The healthcare costs associated with acute kidney injury (AKI) exceed $9 billion annually in the U.S., highlighting a significant unmet medical need[389] - The company aims to leverage its management team's expertise and network to identify and develop new product candidates beyond kidney disease[386] Accounting Policies - The company accounts for stock-based compensation using the Black-Scholes option-pricing model, recognizing expenses over the requisite service period[429] Off-Balance Sheet Arrangements - The company has no off-balance sheet arrangements as of December 31, 2025[424]

Revenue Growth - Fourth Quarter Consolidated Net Revenues reached $58.80 million, a 131.8% increase year-over-year from $25.37 million in Q4 2024[2] - Net Revenues from Light Electric Vehicles (LEV) surged by 524.1% year-over-year to $12.92 million, compared to $2.07 million in Q4 2024[2] - Net Revenues from the Battery Raw Materials Segment (Hitrans) skyrocketed by 944.1% year-over-year to $27.98 million, up from $2.68 million in Q4 2024[2] - Full Year Consolidated Net Revenues reached $195.19 million, an 11% increase from $176.61 million in 2024[15] - Net Revenues from the Hitrans segment increased by 123% year-over-year to $89.21 million, compared to $40.03 million in 2024[17] - CBAK Energy reported net revenues of $195.19 million for the year ended December 31, 2025, an increase of 10.0% from $176.61 million in 2024[36] Profitability and Loss - Gross profit for the fourth quarter was $4.28 million, with a gross margin of 7.3%, down from a gross profit of $3.31 million and a margin of 13.1% in Q4 2024[10] - The company's gross profit decreased to $18.42 million in 2025, down from $41.78 million in 2024, reflecting a gross margin decline[36] - Operating loss for the fiscal year 2025 was $18.44 million, compared to an operating income of $8.79 million in 2024[22] - Operating income turned negative with a loss of $18.44 million in 2025, compared to a profit of $8.79 million in 2024[36] - The company reported a net loss attributable to shareholders of $9.38 million in 2025, compared to a profit of $11.79 million in 2024[36] Research and Development - Research and development (R&D) expenses in Q4 2025 rose to $5.30 million, compared to $3.80 million in Q4 2024[11] - Research and development expenses increased to $15.80 million in 2025, up from $13.01 million in 2024, indicating a focus on innovation[36] Assets and Liabilities - Cash and cash equivalents as of December 31, 2025, were $75.68 million, up from $60.79 million as of December 31, 2024[23] - Total current assets rose to $180.64 million in 2025, compared to $141.40 million in 2024, driven by increases in cash and inventories[33] - Total liabilities increased significantly to $316.70 million in 2025, up from $182.15 million in 2024, primarily due to higher trade payables[34] - CBAK Energy's total assets grew to $426.18 million in 2025, up from $302.22 million in 2024, reflecting expansion efforts[33] Capital Expenditures - Capital expenditures for 2025 were $44.65 million, primarily for the construction and equipping of new production facilities[23] Operational Footprint - The company has multiple operating subsidiaries and a large-scale R&D and production base in Dalian, indicating a strong operational footprint in China[27] - CBAK Energy is engaged in the development of new energy high power lithium and sodium batteries, targeting electric vehicles and energy storage applications[27]

Financial Performance - Total expenses increased from $5.76 million in 2024 to $13.20 million in 2025, representing a 129% increase[157]. - The net loss attributable to shareholders increased from $6.35 million in 2024 to $19.53 million in 2025, marking a 208% increase[157]. - The company experienced a loss of approximately $3.59 million on digital assets in 2025, with no digital assets held in 2024[170]. - The company expects to continue incurring net losses and negative cash flow from operations, raising substantial doubt regarding its ability to continue as a going concern[179]. Expenses Breakdown - General and administrative expenses rose from $4.20 million in 2024 to $8.82 million in 2025, primarily due to a $1.4 million increase in investor relation fees and a $3.0 million increase in consultant fees[158]. - Research and development expenses decreased significantly from $1.20 million in 2024 to $0.18 million in 2025, a reduction of approximately 85%[159]. - Credit loss expense for short-term note receivable surged from $0.36 million in 2024 to $4.20 million in 2025, attributed to Marizyme's debt increasing from $2.4 million to $4.9 million[160]. - Interest expense increased to $0.99 million in 2025 from $0.91 million in 2024, due to higher interest rates on short-term promissory notes[167]. Cash Flow and Financing Activities - Net cash used in operating activities was $7.0 million for the year ended December 31, 2025, primarily due to a loss from continuing operations of $16.9 million[191]. - Net cash used by investing activities was approximately $15.8 million in 2025, primarily due to purchases of digital assets totaling $16.5 million[193]. - Net cash provided by financing activities was $41.0 million in 2025, resulting from the issuance of preferred shares amounting to $38.9 million[195]. - The company raised approximately $45.7 million in new equity during the year ended December 31, 2025, compared to $9.0 million in 2024, highlighting a significant increase in financing activities[180]. Stock and Debt Transactions - Following a reverse stock split on November 5, 2024, the outstanding common stock increased by approximately 192% due to conversions of Series B Preferred Stock[154]. - The company recognized a gain of approximately $56,000 on the voluntary conversion of convertible debt into common stock during the year ended December 31, 2024, with a fair value of approximately $674,000 for 58,378 shares issued at a weighted average share price of $13.00[171]. - A loss on debt extinguishment of approximately $57,000 was recorded in 2024, primarily due to the repayment of the 2024 Alpha Debenture, resulting in a net loss of approximately $68,000 offset by a gain of approximately $13,000 from the issuance of Series A-2 Preferred Stock[172]. - The company issued 45,496 shares of common stock with a fair value of approximately $903,000 for monthly redemptions of $660,000 principal, resulting in a loss of approximately $209,000 during the year ended December 31, 2024[173]. - The company settled $395,000 of outstanding accounts payable for a gain of approximately $348,000 in 2024[174]. Financial Position - As of December 31, 2025, the company had approximately $19.3 million in cash and an accumulated deficit of $140.0 million, indicating a weak financial position[177].